Drug Approval | July 22, 2024
Briefs: Zydus Lifesciences and Divi's Laboratories
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Key takeaways of Q3FY22 quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
